- Home
- MVST vs WVE Comparison
MVST vs WVE Comparison
Compare MVST & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- WVE
- Stock Information
- Founded
- MVST 2006
- WVE 2012
- Country
- MVST United States
- WVE Singapore
- Employees
- MVST N/A
- WVE N/A
- Industry
- MVST Industrial Machinery/Components
- WVE Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- WVE Health Care
- Exchange
- MVST Nasdaq
- WVE Nasdaq
- Market Cap
- MVST 848.0M
- WVE 915.6M
- IPO Year
- MVST N/A
- WVE 2015
- Fundamental
- Price
- MVST $3.84
- WVE $6.73
- Analyst Decision
- MVST Strong Buy
- WVE Strong Buy
- Analyst Count
- MVST 1
- WVE 14
- Target Price
- MVST $6.00
- WVE $20.50
- AVG Volume (30 Days)
- MVST 7.3M
- WVE 3.6M
- Earning Date
- MVST 11-10-2025
- WVE 11-10-2025
- Dividend Yield
- MVST N/A
- WVE N/A
- EPS Growth
- MVST N/A
- WVE N/A
- EPS
- MVST N/A
- WVE N/A
- Revenue
- MVST $444,504,000.00
- WVE $109,230,000.00
- Revenue This Year
- MVST $24.14
- WVE N/A
- Revenue Next Year
- MVST $28.49
- WVE $6.24
- P/E Ratio
- MVST N/A
- WVE N/A
- Revenue Growth
- MVST 19.82
- WVE 103.75
- 52 Week Low
- MVST $0.43
- WVE $5.28
- 52 Week High
- MVST $7.12
- WVE $16.71
- Technical
- Relative Strength Index (RSI)
- MVST 33.26
- WVE 37.36
- Support Level
- MVST $4.55
- WVE $6.72
- Resistance Level
- MVST $5.30
- WVE $8.08
- Average True Range (ATR)
- MVST 0.42
- WVE 0.70
- MACD
- MVST -0.24
- WVE -0.16
- Stochastic Oscillator
- MVST 10.17
- WVE 4.32
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About WVE Wave Life Sciences Ltd.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.